Bacterial Vaginosis Drugs Market By Route of Administration (Oral Route : Metronidazole, Tinidazole, Clindamycin, Secnidazole; Topical Route : Metronidazole, Clindamycin, Normal pH Restoration Gels (VivaGel®, Canesbalance)) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

The distribution pattern regarding occurrence of bacterial vaginosis is 18.8 % in celibate women, 25 % in pregnant women and 31.7 % in women who have ever been pregnant is considered as per the research findings of Center for Disease Control and Prevention. The risk factors associated with the disease etiology of bacterial vaginosis is pelvic inflammatory disease, preterm delivery of infants, urinary tract infection and sexually transmitted diseases (STD). The product pipeline in phase 3 for treatment of bacterial vaginosis are Metronidazole oral tablets 500mg | 1% SPL7013 Gel, GDC-229, Clindamycin 100mg and Ketoconazole 400mg and Association of metronidazole; nystatin and dexamethasone.

Oral route comprises of Metronidazole, Tinidazole, clindamycin and Secnidazole. The topical route includes Metronidazole, Clindamycin and normal pH restoration gels. The normal pH restoration gels is further sub segmented as Canesbalance and VivaGel®. Recent trends prevailing in the bacterial vaginosis drugs is understood by the inclusion of market size and forecast in the scope of the report.

Following geographical segmentation with their major countries have been included in the scope of the report:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market estimate and forecast for duration 2015-2025 has been reported for the major countries included in the regional segments to understand the country cross sectional market of the bacterial vaginosis drugs.

The competitive landscape and attractive investment proposition gives clear idea that the first line treatment drugs employed for the treatment of bacterial vaginosis and the product pipeline of key manufacturers engaged in the bacterial vaginosis treatment industry. Collaborative partnership between the key players to promote recently approved drugs are mentioned in the company profiles considered for bacterial vaginosis drugs market. The major players in global bacterial vaginosis drugs market are Sanofi Aventis, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Inc., Starpharma Holdings Limited and Symbiomix Therapeutics.

Bacterial Vaginosis Drugs Market

Choose License Type
Published Date:  Nov 2017
Category:  Pharmaceuticals
Report ID:   58853
Report Format:   PDF
Pages:   120
Rating:    4.4 (55)
Connect With Us
24/7 Research Support